ClinicalTrials.gg
CompletedNCT04884191Updated Jun 1, 2022Results posted

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

A Phase 2 interventional study of Pacritinib in Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis and Post- Essential Thrombocythemia Myelofibrosis, sponsored by CTI BioPharma. Completed at 62 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-01.

Sponsored by CTI BioPharma (part of Swedish Orphan Biovitrum) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 9 months after the study started (first participant enrolled Jul 2017, registered May 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing pacritinib in Primary Myelofibrosis — 6 open to participants now, 8 under way, 1 of them phase 3. pacritinib · Primary Myelofibrosis.

Enrollment
4th of 18
165 · median 35
Started
2017
with 2 others
Phase 2
8 of 18
4 open now
Registered
13th of 18
by date
Lead sponsor
5 of 18
CTI BioPharma

Among the 18 studies testing pacritinib in Primary Myelofibrosis, this one is the 4th largest by enrollment, is one of 3 that started in 2017, is one of 8 in phase 2, and was the 13th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

6 of the 18 studies testing pacritinib in Primary Myelofibrosis are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pacritinib

pacritinib: first FDA approval 2022 (VONJO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing pacritinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This was an open-label, randomized, dose-finding study in patients with primary or secondary MF (Dynamic International Prognostic Scoring System [DIPSS] risk score of Intermediate-1 to High-Risk) who were previously treated with ruxolitinib. The study was designed to support a pacritinib dosage selection decision with evaluation of 3 dosages.

03

Conditions studied

  • Primary Myelofibrosis
  • Post-Polycythemia Vera Myelofibrosis
  • Post- Essential Thrombocythemia Myelofibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. PMF, PPV-MF, or PET-MF (as defined by Tefferi and Vardiman 2008)
  2. DIPSS Intermediate-1, Intermediate -2, or High-risk (Passamonti et al 2010)
  3. Prior ruxolitinib treatment with failure to benefit or intolerance as defined by at least one of the following:

    1. Treatment for ≥3 months with inadequate efficacy response defined as \<10% SVR by MRI or \<30% decrease from baseline in spleen length by physical examination or regrowth to these parameters following an initial response; and/or
    2. Treatment for ≥28 days complicated by either

    i. Development of a red blood cell (RBC) transfusion requirement (at least 2 units/month for 2 months) ii. National Cancer Institute (NCI) grade ≥3 AEs of thrombocytopenia, anemia, hematoma, and/or hemorrhage while being treated with a dosage of \<20 mg BID

  4. Palpable splenomegaly ≥5 cm below the lower costal margin (LCM) in the midclavicular line as assessed by physical examination
  5. TSS of ≥10 on the MPN-SAF TSS 2.0 or patients with a single symptom score of ≥5 or 2 symptoms of ≥3, including only the symptoms of left upper quadrant pain, bone pain, itching, or night sweats
  6. Age ≥18 years old
  7. (ECOG) performance status 0 to 2
  8. Peripheral blast count of \<10% throughout the Screening period
  9. of >500/μL
  10. Adequate liver and renal function, defined by liver transaminases ( [AST]/serum glutamic-oxaloacetic transaminase [SGOT] and alanine aminotransferase [ALT]/serum glutamic-pyruvic transaminase [SGPT]), ≤3 × the (ULN) (AST/ALT ≤5 × ULN, if transaminase elevation is related to MF), direct ≤4× ULN, and creatinine ≤2.5 mg/dL
  11. Adequate coagulation function, defined by (PT)/international normalized ratio (INR), partial thromboplastin time (PTT), or thrombin time (TT) of ≤1.5 × ULN
  12. Left ventricular cardiac of ≥45% by echocardiogram or multigated acquisition (MUGA) scan
  13. If fertile, willing to use effective methods during the study
  14. Willing to undergo and able to tolerate frequent MRI or CT scan assessments during the study
  15. Able to understand and willing to complete symptom assessments using a PRO instrument
  16. Provision of

Exclusion criteria

Exclusion Criteria:

  1. \<6 months
  2. Completed stem cell transplant (allo-SCT) or are eligible for and willing to complete allo-SCT
  3. History of splenectomy or planning to undergo splenectomy
  4. Splenic irradiation within the last 6 months
  5. Previously treated with pacritinib
  6. Patients receiving high-dose ruxolitinib (more than 10 mg BID or 20 mg QD) who cannot tolerate tapering down ruxolitinib to 10 mg BID or less prior to the first dose of pacritinib
  7. Treatment with anticoagulation or antiplatelet agents, except for aspirin dosages of ≤100 mg per day, within the last 2 weeks
  8. Treatment with a strong inhibitor or a strong cytochrome P450 inducer within the last 2 weeks
  9. Treatment with medications that can prolong the within the last 2 weeks
  10. Treatment with an experimental therapy within the last 28 days
  11. Significant recent bleeding history defined as grade ≥2 within the last 3 months, unless precipitated by an inciting event (eg, surgery, trauma, or injury)
  12. Any history of CTCAE grade ≥2 non-dysrhythmia cardiac conditions within the last 6 months. Patients with asymptomatic grade 2 non-dysrhythmia cardiac conditions may be considered for inclusion, with the approval of the medical monitor, if stable and unlikely to affect patient safety.
  13. Class II, III, or IV congestive heart failure
  14. Any history of CTCAE grade ≥2 cardiac dysrhythmias within the last 6 months. Patients with non-QTc CTCAE grade 2 cardiac dysrhythmias may be considered for inclusion, with the approval of the medical monitor, if the dysrhythmias are stable, asymptomatic, and unlikely to affect patient safety.
  15. QTc prolongation >450 ms based on the mean of triplicate ECGs or other factors that increase the risk for QT interval prolongation (eg, heart failure, hypokalemia [defined as serum potassium \<3.0 mEq/L that is persistent and to correction], family history of long QT interval syndrome, or concomitant use of medications that may prolong QT interval)
  16. Any active gastrointestinal or metabolic condition that could interfere with absorption of oral medication
  17. Active or uncontrolled inflammatory or chronic functional bowel disorder such as Crohn's Disease, inflammatory bowel disease, chronic diarrhea, or constipation
  18. Other within the last 3 years, other than curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, organ-confined or treated nonmetastatic prostate cancer with negative prostate-specific antigen, in situ breast carcinoma after complete surgical resection, or superficial transitional cell bladder carcinoma
  19. Uncontrolled intercurrent illness, including, but not limited to, ongoing active infection or psychiatric illness or social situation that, in the judgment of the treating physician, would limit compliance with study requirements
  20. Known seropositivity for
  21. Known active hepatitis A, B, or C virus infection
  22. Women who are pregnant or lactating
  23. Concurrent enrollment in another interventional trial
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    Pacritinib 100 mg QD

    Drug: Pacritinib

  • Experimental
    Pacritinib 100 mg BID

    Drug: Pacritinib

  • Experimental
    Pacritinib 200 mg BID

    Drug: Pacritinib

Interventions

06

What researchers measure

Primary outcomes

  1. Spleen Volume Reduction Response (≥ 35%)

    Number of patients achieving a ≥ 35% spleen volume reduction (SVR) as measured by magnetic resonance imaging (MRI, preferred) or computed tomography (CT) scans

    Time frame: From Baseline to Weeks 12 and 24

  2. Percent Change in Spleen Volume

    Percent change from baseline

    Time frame: From Baseline to Weeks 12 and 24

  3. Total Symptom Score Analysis

    Proportion of patients with ≥ 50% reduction in Total Symptom Score from baseline as assessed by the validated PRO instrument MPN-SAF TSS 2.0

    Time frame: From Baseline to Weeks 12 and 24

  4. Patient Global Impression Assessment

    Number of patients with improvement in PGIA. The Patient Global Impression Assessment questionnaire was completed at the end of Week 12 and end of Week 24. The scores were summarized by treatment group at each visit.

    Time frame: From Baseline to Weeks 12 and 24

Secondary outcomes

  1. Spleen Length Reduction

    Rate of reduction in spleen length from baseline

    Time frame: From Baseline to Weeks 24

  2. Frequency of RBC's or Platelet Transfusions

    Number of patients

    Time frame: At week 24

  3. Eastern Cooperative Oncology Group Performance Status

    0 = Fully active, able to carry on all pre-disease performance without restriction 1. = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work 2. = Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours 3. = Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours 4. = Completely disabled; cannot carry on any selfcare; totally confined to bed or chair 5. = Dead

    Time frame: At weeks 4, 12, 24, and 30 days post End-of-Treatment visit

  4. Number of Participants With Adverse Events

    Time frame: Randomization through 30 days post End-of-Treatment visit

07

Results

Posted Jun 1, 2022

Participant flow

Participant flow — Overall Study
MilestonePacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BID
Started555555
Completed525554
Not completed301

Outcome measures

PrimarySpleen Volume Reduction Response (≥ 35%)

Number of patients achieving a ≥ 35% spleen volume reduction (SVR) as measured by magnetic resonance imaging (MRI, preferred) or computed tomography (CT) scans

Time frame:
From Baseline to Weeks 12 and 24
Reported as:
Count of participants · Participants
Spleen Volume Reduction Response (≥ 35%)
ParticipantsPacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BID
End of Week 12022
End of Week 24015
PrimaryPercent Change in Spleen Volume

Percent change from baseline

Time frame:
From Baseline to Weeks 12 and 24
Reported as:
Mean · percent change from baseline
Percent Change in Spleen Volume
percent change from baselinePacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BID
Week 123.19 ± 22.6136.37 ± 31.110-3.60 ± 26.610
Week 24-2.43 ± 17.6080.65 ± 20.589-11.30 ± 26.417
PrimaryTotal Symptom Score Analysis

Proportion of patients with ≥ 50% reduction in Total Symptom Score from baseline as assessed by the validated PRO instrument MPN-SAF TSS 2.0

Time frame:
From Baseline to Weeks 12 and 24
Reported as:
Count of participants · Participants
Total Symptom Score Analysis
ParticipantsPacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BID
End of Week 12112
End of Week 24202
PrimaryPatient Global Impression Assessment

Number of patients with improvement in PGIA. The Patient Global Impression Assessment questionnaire was completed at the end of Week 12 and end of Week 24. The scores were summarized by treatment group at each visit.

Time frame:
From Baseline to Weeks 12 and 24
Reported as:
Count of participants · Participants
Patient Global Impression Assessment
ParticipantsPacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BID
Week 12 - Any Improved172123
Week 12 -No Change658
Week 12 -Any Worse883
Week 24 - Any Improved101318
Week 24 -No Change651
Week 24 -Any Worse532
SecondarySpleen Length Reduction

Rate of reduction in spleen length from baseline

Time frame:
From Baseline to Weeks 24
Reported as:
Mean · cm
Spleen Length Reduction
cmPacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BID
Spleen Length Reduction12.42 ± 5.60211.48 ± 6.50111.63 ± 7.131
SecondaryFrequency of RBC's or Platelet Transfusions

Number of patients

Time frame:
At week 24
Reported as:
Mean · transfusions/month
Frequency of RBC's or Platelet Transfusions
transfusions/monthPacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BID
Frequency of RBC's or Platelet Transfusions2.27 ± 2.9871.18 ± 2.5532.25 ± 2.345
SecondaryEastern Cooperative Oncology Group Performance Status

0 = Fully active, able to carry on all pre-disease performance without restriction 1. = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work 2. = Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours 3. = Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours 4. = Completely disabled; cannot carry on any selfcare; totally confined to bed or chair 5. = Dead

Time frame:
At weeks 4, 12, 24, and 30 days post End-of-Treatment visit
Reported as:
Count of participants · Participants
Eastern Cooperative Oncology Group Performance Status
ParticipantsPacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BID
Week 4 - 0101113
Week 4 - 1282731
Week 4 - 29168
Week 4 - 3200
Week 4 - 4000
Week 4 - 5000
Week 12 - 011914
Week 12 - 1202319
Week 12 - 28108
Week 12 - 3112
Week 12 - 4000
Week 12 - 5000
Week 24 - 010610
Week 24 - 1121512
Week 24 - 2456
Week 24 - 3000
Week 24 - 4000
Week 24 - 5000
End of Treatment - 01188
End of Treatment - 1192322
End of Treatment - 251011
End of Treatment - 3112
End of Treatment - 4000
End of Treatment - 5000
SecondaryNumber of Participants With Adverse Events
Time frame:
Randomization through 30 days post End-of-Treatment visit
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BID
Number of Participants With Adverse Events495154

Adverse events

Collected over The end of assigned study drug + 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pacritinib 100 mg QD6/52 (11.5%)19/52 (36.5%)24/52 (46.2%)
Pacritinib 100 mg BID4/55 (7.3%)20/55 (36.4%)34/55 (61.8%)
Pacritinib 200 mg BID5/54 (9.3%)25/54 (46.3%)36/54 (66.7%)
Most frequent serious events
Showing 10 of 77
Most frequent serious events
EventPacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BID
PneumoniaInfections and infestations2/522/555/54
PyrexiaGeneral disorders3/522/553/54
DehydrationMetabolism and nutrition disorders0/523/552/54
General physical health deteriorationGeneral disorders2/520/550/54
EpistaxisRespiratory, thoracic and mediastinal disorders2/520/550/54
Gastrointestinal haemorrhageGastrointestinal disorders0/520/552/54
SepsisInfections and infestations1/521/552/54
Clostridium difficile colitisInfections and infestations0/521/552/54
GastroenteritisInfections and infestations0/521/552/54
Renal failure acuteRenal and urinary disorders1/520/552/54
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BID
DiarrhoeaGastrointestinal disorders6/528/5514/54
ThrombocytopeniaBlood and lymphatic system disorders3/525/559/54
NauseaGastrointestinal disorders7/527/553/54
FatigueGeneral disorders1/527/555/54
AnaemiaBlood and lymphatic system disorders1/523/556/54
Decreased appetiteMetabolism and nutrition disorders3/522/553/54
BronchitisInfections and infestations3/521/551/54
EpistaxisRespiratory, thoracic and mediastinal disorders2/521/553/54
Ejection fraction decreasedInvestigations1/523/552/54
PyrexiaGeneral disorders1/523/551/54

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BIDTotal
<=18 years0000
Between 18 and 65 years16111643
>=65 years364438118
Age, Continuous
Age, Continuous(years)Pacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BIDTotal
Mean69 ± 8.868.9 ± 6.968.1 ± 8.7668.7 ± 8.14
Sex: Female, Male
Sex: Female, Male(Participants)Pacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BIDTotal
Female21262269
Male31293292
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BIDTotal
American Indian or Alaska Native0011
Asian2114
Native Hawaiian or Other Pacific Islander0000
Black or African American1045
White444748139
More than one race0000
Unknown or Not Reported57012
BMI
BMI(kg/m^2)Pacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BIDTotal
Mean25.1 ± 3.7927.2 ± 4.1126.4 ± 526.3 ± 4.4
ECOG PS
ECOG PS(participants)Pacritinib 100 mg QDPacritinib 100 mg BIDPacritinib 200 mg BIDTotal
011141742
132292990
2912829
08

Study locations

62 sites
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • City of Hope
    Duarte, California 91010, United States
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • UCLA Jonsson Comprehensive Cancer Center
    Los Angeles, California 90095, United States
  • Stanford Cancer Institute
    Stanford, California 94305, United States
  • Yale School of Medicine
    New Haven, Connecticut 06520, United States
  • Medical Faculty Associates, Inc.
    Washington, District of Columbia 20037, United States
  • Florida Cancer Specialists & Research Institute
    Fort Myers, Florida 33901, United States
  • Florida Cancer Specialists & Research Institute
    Saint Petersburg, Florida 33705, United States
  • Florida Cancer Specialists & Research Institute
    West Palm Beach, Florida 33401, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • The University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Ochsner Medical Center
    New Orleans, Louisiana 70121, United States
  • Saint Agnes Hospital
    Baltimore, Maryland 21229, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan Comprehensive Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Washington University School of Medicine in St. Louis
    Saint Louis, Missouri 63110, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Columbia University
    New York, New York 10032, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Duke University Hospital
    Durham, North Carolina 27710, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Texas Health Science Center at San Antonio School of Medicine
    San Antonio, Texas 78229, United States
  • University of Utah School of Medicine
    Salt Lake City, Utah 84112, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • CHU Hopital Sud
    Amiens, 80054, France
  • Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez
    Lille Cedex, 59037, France
  • CHU de Nimes - Hopital Universitaire Caremeau
    Nîmes, 30029, France
  • Hôpital Saint-Louis
    Paris, 75010, France
  • CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque
    Pessac, 33604, France
  • Centre Hospitalier Lyon-Sud
    Pierre-Bénite, 69495, France
  • Centre Hospitalier Universitaire de Toulouse- Hôpital Purpan
    Toulouse Cedex, 31059, France
  • SE AOK I. sx. Belgyogyaszati Klinika
    Budapest, 1083, Hungary
  • Debreceni Egyetem Klinikai Központ
    Debrecen, 4032, Hungary
  • Somogy Megyei Kaposi Mór Oktató Kórház
    Kaposvár, 7400, Hungary
  • Azienda Ospedaliero-Universitaria Careggi
    Firenze, 50134, Italy
  • Istituto Scientifico Romagnolo per lo Studio e la Cura Dei Tumori
    Meldola, 47014, Italy
  • ASST Monza - Ospedale San Gerardo
    Monza, 20900, Italy
  • Yeungnam University Medical Center
    Daegu, 42415, Korea, Republic of
  • Severance Hospital
    Seoul, 03722, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, 06591, Korea, Republic of
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Clínica Universidad de Navarra
    Pamplona, 31008, Spain
  • Skane University Hospital Lund
    Lund, 22185, Sweden
  • Orebro University Hospital
    Örebro, 70185, Sweden
  • Beatson West of Scotland Cancer Center
    Glasgow, G12 0YN, United Kingdom
  • Barts Health NHS Trust - The Royal London Hospital
    London, E1 2ES, United Kingdom
  • Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
    London, SE1 9RT, United Kingdom
  • Imperial College Healthcare NHS Trust - Hammersmith Hospital
    London, W12 0HS, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
  • Oxford University Hospitals NHS Trust - Churchill Hospital
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Publications

  • Verstovsek S, Mesa R, Talpaz M, Kiladjian JJ, Harrison CN, Oh ST, Vannucchi AM, Rampal R, Scott BL, Buckley SA, Craig AR, Roman-Torres K, Mascarenhas JO. Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. Haematologica. 2022 Jul 1;107(7):1599-1607. doi: 10.3324/haematol.2021.279415. PubMed 34551507 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Sep 2019, 25 months.

Results were first posted in Jun 2022, 2 years 8 months after primary completion.

Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's 25 months is below that.

Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2021
First posted
May 12, 2021
StartActual
Jul 31, 2017
Primary completionActual
Sep 4, 2019
CompletionActual
Sep 4, 2019
Results first posted
Jun 1, 2022
Last update
Jun 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04884191
Lead sponsor
CTI BioPharma
Responsible party
Sponsor
First posted
May 12, 2021
Start date
Jul 31, 2017
Primary completion
Sep 4, 2019
Completion
Sep 4, 2019
Results posted
Jun 1, 2022
Last update
Jun 1, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pacritinib

Start the discussion